Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early Appearance of Coronavirus Disease 2019 Associated Pulmonary Infiltrates During Daily Radiotherapy Imaging for Lung Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lokalanæstesitorakoskopi ved udredning af recidiverende pleuraeffusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: We investigated the clinical applicability of a novel liquid fiducial marker (LFM) for image-guided pencil beam scanned (PBS) proton therapy (PBSPT) of locally advanced lung cancer (LALC).

MATERIALS AND METHODS: The relative proton stopping power (RSP) of the LFM was calculated and measured. Dose perturbations of the LFM and three solid markers, in a phantom, were measured. PBSPT treatment planning on computer tomography scans of five patients with LALC with the LFM implanted was performed with 1-3 fields.

RESULTS: The RSP was experimentally determined to be 1.164 for the LFM. Phantom measurements revealed a maximum relative deviation in dose of 4.8% for the LFM in the spread-out Bragg Peak, compared to 12-67% for the solid markers. Using the experimentally determined RSP, the maximum proton range error introduced by the LFM is about 1mm. If the marker was displaced at PBSPT, the maximum dosimetric error was limited to 2 percentage points for 3-field plans.

CONCLUSION: The dose perturbations introduced by the LFM were considerably smaller than the solid markers investigated. The RSP of the fiducial marker should be corrected in the treatment planning system to avoid errors. The investigated LFM introduced clinically acceptable dose perturbations for image-guided PBSPT of LALC.

Original languageEnglish
JournalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume122
Issue number3
Pages (from-to)393-399
Number of pages7
ISSN0167-8140
DOIs
Publication statusPublished - Mar 2017

    Research areas

  • Fiducial Markers, Humans, Lung Neoplasms, Phantoms, Imaging, Proton Therapy, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Tomography, X-Ray Computed, Journal Article

ID: 52407227